AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Interleukin-36 receptor antagonist protein including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Interleukin-36 receptor antagonist protein therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Interleukin-36 receptor antagonist protein, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Interleukin-36 receptor antagonist protein. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Interleukin-36 receptor antagonist protein. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Interleukin-36 receptor antagonist protein includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Interleukin-36 receptor antagonist protein
partner:
Reaxense
upacc:
Q9UBH0
UPID:
I36RA_HUMAN
Alternative names:
FIL1 delta; IL-1-related protein 3; Interleukin-1 HY1; Interleukin-1 delta; Interleukin-1 family member 5; Interleukin-1 receptor antagonist homolog 1; Interleukin-1-like protein 1
Alternative UPACC:
Q9UBH0; A8K2I4; Q56AT9; Q7RTZ6
Background:
The Interleukin-36 receptor antagonist protein, known by alternative names such as FIL1 delta and Interleukin-1 family member 5, plays a crucial role in modulating inflammation. It inhibits the activity of interleukin-36 by binding to receptor IL1RL2, preventing its association with the coreceptor IL1RAP, thus impacting the IL-36 signaling system present in epithelial barriers and contributing to local inflammatory responses.
Therapeutic significance:
Given its pivotal role in skin inflammation and innate immune response, particularly in conditions like Psoriasis 14, pustular, characterized by severe skin eruptions and inflammation, the Interleukin-36 receptor antagonist protein represents a promising target for therapeutic intervention. Understanding its function could lead to novel treatments for inflammatory skin diseases.
